Bright Minds Biosciences

DRUGPhase 2

New York, United StatesFounded 2017brightmindsbio.com

Bright Minds Biosciences is pioneering a new class of CNS therapeutics by designing highly selective serotonin receptor agonists. The company's mission is to address significant unmet needs in neuropsychiatry, moving beyond traditional approaches to create drugs with novel mechanisms of action. Its lead programs target 5-HT receptors implicated in mood, cognition, and seizure control, with its most advanced candidate, BMB-101, in Phase 2 development for treatment-resistant depression. The company's strategic direction involves advancing its clinical pipeline while exploring the potential of its platform in additional CNS indications.

Market Cap

$701.0M

Founded

2017

Employees

11-50

Focus

Biotech

DRUG · Stock Price

USD 71.62+63.62 (+795.25%)

Historical price data

AI Company Overview

Technology Platform

Proprietary drug discovery platform focused on designing highly selective serotonin receptor (5-HT) agonists to treat neuropsychiatric disorders with improved efficacy and safety profiles.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
BMB-101 + Placebo	Prader-Willi Syndrome	Phase 2
BMB-101	Absence Epilepsy	Phase 2
BMB-101 + Placebo	Healthy	Phase 1

Funding History

Total raised: $13M

IPO$10MUndisclosedMar 3, 2021

Seed$3MUndisclosedJun 15, 2019

Opportunities

Significant opportunities exist in large, underserved neuropsychiatric markets like treatment-resistant depression and ADHD.

Positive clinical data could lead to high-value partnerships or acquisition interest.

The selective serotonin platform also offers potential for expansion into other CNS disorders such as anxiety, addiction, and chronic pain.

Risk Factors

Key risks include clinical trial failure, the high placebo effect in psychiatric studies, future dilution from necessary capital raises, and intense competition in CNS therapeutics.

The novel mechanism, while a differentiator, is also unproven at commercial scale.

Competitive Landscape

Competes with large pharma (e.g., J&J) and biotechs in depression, and established non-stimulant therapies in ADHD. Differentiation is based on highly selective receptor targeting aiming for efficacy without the side effects (e.g., hallucinations) associated with less selective or psychedelic-derived approaches.

Publications

Pipeline